-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710

Benzinga·08/11/2026 13:51:35
Listen to the news
Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.